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Abstract 
Background: Patients with cancer who develop small bowel obstruction are at high risk of 
malnutrition and morbidity following compromise of gastrointestinal tract continuity. This study 
aimed to characterise current management and outcomes following malignant small bowel 
obstruction. 
 
Methods: A prospective, multicentre cohort study of patients with small bowel obstruction who 
presented to UK hospitals between 16th January and 13th March 2017. Patients who 
presented with small bowel obstruction due to primary tumours of the intestine (excluding left-
sided colonic tumours) or disseminated intra-abdominal malignancy were included. Outcomes 
included 30-day mortality and in-hospital complications. Cox-proportional hazards models 
were used to generate adjusted effects estimates, which are presented as hazard ratios (HR) 
alongside the corresponding 95% confidence interval (95% CI). The threshold for statistical 
significance was set at the level of P ≤ 0.05 a-priori. 
 
Results: 205 patients with malignant small bowel obstruction presented to emergency surgery 
services during the study period. Of these patients, 50 had obstruction due to right sided colon 
cancer, 143 due to disseminated intraabdominal malignancy, 10 had primary tumours of the 
small bowel and 2 patients had gastrointestinal stromal tumours. In total 100 out of 205 
patients underwent a surgical intervention for obstruction. 30-day in-hospital mortality rate was 
11.3% for those with primary tumours and 19.6% for those with disseminated malignancy. 
Severe risk of malnutrition was an independent predictor for poor mortality in this cohort 
(adjusted HR 16.18, 95% CI 1.86 to 140.84, p = 0.012). Patients with right-sided colon cancer 
had high rates of morbidity. 
 
Conclusions: Mortality rates were high in patients with disseminated malignancy and in those 
with right sided colon cancer. Further research should identify optimal management strategy 
to reduce morbidity for these patient groups. 
4 
 
Background 
Small bowel obstruction affects between 3% and 15% of patients with malignancy[1]. 
Obstruction may originate from primary tumours of the gastrointestinal tract or as a result of 
metastatic disease, typically in the peritoneum. Obstruction may compromise physiological 
function of the bowel leading to substantial morbidity and even death. Although obstruction 
resolves spontaneously in up to one third of patients, many require surgical intervention to 
restore the function of the gastrointestinal tract and avert further complications[1]. Poor 
nutritional status and cachexia are both independent predictors for poor survival in patients 
with advanced cancer [2]. Restoring optimal function of the gastrointestinal tract is important 
for both comfort and nutritional input[1, 3].  At present there are few data on the best time to 
intervene and who may benefit from surgical intervention. Limited data available are derived 
from small single centre retrospective studies[3–5]. Furthermore, most of these data come 
from patients with specific malignancies e.g. gynaecological, making it difficult to extrapolate 
to a wider population and real-world practice. 
  
To address these shortcomings, we conducted a national, prospective, multicentre cohort 
study. investigating management and outcomes of patients with small bowel obstruction from 
any cause. In this study, we report the management and outcomes of patients from the pre-
specified subgroup of patients with cancer. 
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Methods 
The National Audit of Small Bowel Obstruction (NASBO) was a trainee-led and trainee-
delivered multi-centre, prospective cohort study of all patients admitted with small bowel 
obstruction between 16th January and 13th March 2017[6] . NASBO was widely supported by 
stakeholder partners including specialty associations, Royal Colleges, and charity funders. All 
acute UK hospitals that performed emergency general surgery were eligible to contribute 
patient data. Hospitals were recruited through the NASBO network, personal contacts, and 
social media[7]. This study is reported in line with the STrengthening the Reporting of 
OBservational studies in Epidemiology (STROBE) and Statistical Analyses and Methods in 
the Published Literature (SAMPL) guidelines[8, 9]. Contributions of the steering group and 
collaborators are presented in Appendices A & B respectively and are reported in line with 
collaborative authorship guidelines[10]. Local collaborators were responsible for registering 
NASBO at each site and securing Caldicott Guardian permissions. This study was 
submitted  to NHS East Scotland Research and Ethics Committee (NR/1610AB10) and 
received confirmation that national research ethics approval was not required. 
  
Patients aged over 16 years old with a high clinical suspicion of small bowel obstruction were 
eligible for inclusion within this study. Patients who were pregnant or subsequently found not 
to have small bowel obstruction were excluded from the study. Owing to developments in 
colonic stenting in the emergency setting[11], and the possibility of closed loop large bowel 
obstruction compounding the condition, patients with small bowel obstruction due to a left 
sided colonic tumour or large bowel obstruction alone were excluded from the study as their 
clinical management is significantly different. 
  
Data were collected according to the pre-specified study protocol[6]. Variables collected 
included age, sex, comorbidities[12], imaging, management (including operation, with 
immediate operation defined as the decision to operate within 24 hours of presentation and 
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delayed as over 24 hours), nutritional assessment (whether formally or informally assessed 
by clinical team, dietetic review, BMI, nutritional risk index and any supportive interventions) 
and 30-day outcomes. We categorised treatment intent into palliative and active, with the 
definition of palliative being provision of end-of-life care as defined by the treating medical 
team. Outcomes included 30-day survival (for in-hospital mortality), infectious complications 
(surgical site infection (deep and superficial), urinary tract infection, lower respiratory tract 
infection), requirement for unplanned critical care and length of stay. All variables and 
outcomes had clear definitions to ensure standardisation across sites. Collaborators entered 
data into the online secure REDCap database system[13] at the University of Sheffield. 
Cancer diagnoses were categorised into right sided colonic carcinoma, primary small bowel 
tumours, gastrointestinal stromal tumours (GISTs) or disseminated intra-abdominal disease 
(e.g. ovarian, colorectal or peritoneal cancer). GISTs were treated independently from other 
primary small bowel tumours due to their different clinical management (likely to be cured by 
surgery alone in the emergency setting) and propensity to invade adjacent structures. We 
further grouped these into two categories, primary tumours versus disseminated malignancy 
to provide outcome data specific to patients with metastatic disease. 
  
To ensure data accuracy and adequate case ascertainment, validation was performed by local 
investigators independent from the data collection teams. Validation was carried out on key 
fields of 25% of all patient records at each site. Records were selected for re-sampling using 
a random number generator at the coordinating site. Categorical variables were deemed to 
be accurate on exact match and continuous variables when the figure was within 0.5 units of 
the collected data. Accuracy was expressed as a percentage of correct fields out of the total 
fields sampled. 
  
Data were tabulated and compared using simple summary statistics for comparisons across 
treatment groups. The Chi-square and Kruskall-Wallis tests were used to test for differences 
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across categorical and continuous variables respectively. Clinically plausible variables were 
entered into Cox proportional-hazards models in order to adjust for patient level effects. 
Models were clustered by centre to adjust for hospital-level effects. Effects estimates are 
presented as hazard ratios (HR), alongside the corresponding 95% confidence interval (95% 
CI). Model selection was guided by minimisation of the Akaike Information Criterion (AIC). 
Models were examined for first level interactions and those which were found to be significant 
were retained in the model. Due to complexity in management pathways and requirement for 
critical care following operation for patients with malignancy who are being actively (rather 
than palliatively) managed, we repeated the Cox proportional-hazards analysis for patients 
who received critical care. Statistical significance was taken at the level of P ≤ 0.05 a-priori. 
All analyses were performed in R version 3.4.4 (R Foundation for Statistical Computing) using 
the tidyverse and finalfit packages. 
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Results 
NASBO collected data on 2,604 patients from 131 hospitals identified during the study period 
(figure 1). Following screening for eligibility and completeness of data, 2,431 patients were 
included in the national study. Validation of the data fields in the NASBO study confirmed data 
accuracy at 92.4%. Within the whole NASBO cohort, 205 (8.4%) had cancer as the primary 
cause of small bowel obstruction, making cancer the third most common cause of obstruction 
after intra-abdominal adhesions (47.1%) and hernia (17.0%). The most common cause of 
malignant obstruction was disseminated intra-abdominal malignancy (70.0%, 143/205), 
followed by right sided colon cancer (24.4%,50/205), with primary tumours of the small bowel 
(4.9%, 10/205) and gastrointestinal stromal tumours (2/205, 1.0%) accounting for the 
remainder. Data on the remainder of the cohort have been published elsewhere[14]. 
  
Mean age of 205 patients with malignant SBO was 68.8 years (±12.9 years, figure 2). Patients 
presenting with a primary tumour were on average three years older, with more comorbidities 
according to the Charlson Comorbidity Index (CCI), than those with disseminated disease 
(table 1). Malnutrition was common, with 68.8% identified as having at least moderate risk of 
malnutrition, compared with just 41.7% of those with adhesive bowel obstruction. Acute kidney 
injury was common, affecting 23.4% of patients at admission. Patients with cancer related 
SBO were twice as likely to be transferred to surgical care from another inpatient team than 
patients with adhesive SBO who were usually admitted directly under surgery. 
  
Management 
Diagnostic imaging was performed for all but one patient with SBO due to malignancy. For 
patients with disseminated malignancy 80.4% underwent CT scan versus 93.5% for those with 
a primary tumour (table 2). Abdominal plain radiographs, with no additional imaging, were 
performed in 18.9% (27/143) patients with obstruction due to disseminated malignancy. In 
contrast to patients with adhesive bowel obstruction, use of therapeutic oral water-soluble 
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contrast agents was low, with just 3.2% (2/62) of patients with a primary tumour and 13.3% 
(19/143) of patients with disseminated malignancy receiving this intervention. 
  
Characteristics of patients treated with active or palliative intent are presented in figure 2. The 
majority (51.2%, 105/205) of patients did not undergo surgery, with the non-operative group 
mostly comprised of patients with disseminated intra-abdominal malignancy. Of the patients 
who were managed palliatively, 10.5% (4/38) underwent surgery. Of those who underwent 
immediate surgery (table 1S), most patients had right-sided colon cancer (50.0%, 27/54), with 
a smaller proportion of individuals having disseminated intra-abdominal malignancy (37.0%, 
20/54) (Figure 3). Patients with disseminated malignancy were more likely to have operations 
more than 24 hours after admission, table 1S. The most common operation in the right sided 
colon cancer group was small bowel resection with formation of ileostomy/jejunostomy 
(74.4%, 32/43) in contrast to the disseminated malignancy group where primary anastomosis 
without resection (bypass) was most commonly performed (31.9%, 15/47). For those who 
underwent an operation, the mean time to operation was 1.6 (SD 1.8) days in the immediate 
operation group and 6.0 (SD 4.7) days in the delayed operation group. Despite a large 
proportion of patients with cancer being at high risk of malnutrition (table 1) and 45.9% of 
patients being clinically identified as malnourished (94/205), just half of all patients received a 
dietetic or nutrition review as an inpatient and fewer patients still received nutritional 
supplementation, enteral or parenteral, at any point during admission (Table 2S). Patients who 
were identified as malnourished were more likely to receive a dietetic review (70.2% 66/94 
versus 13.2% 14/106). 
  
Outcomes 
Unadjusted in-hospital mortality was significantly higher in patients with malignancy than in 
patients with adhesive small bowel obstruction (11.3% for patients with primary tumours, 
19.6% for those with disseminated malignancy versus 5.7% for those with adhesive 
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obstruction, table 3). Patients with primary tumour as cause for obstruction were more likely 
to have surgery and hence surgical complications, including surgical site infection, 
cardiovascular events, requirement for drainage, reoperation and unplanned admission to 
critical care (table 3). There was no difference in in-hospital mortality between patients with 
malignant small bowel obstruction managed with active or palliative intent (Figure 4). 
  
At univariable level, CCI and moderate or high nutritional risk index were significantly 
associated with higher hazards of mortality. Following adjustment for clinically plausible 
variables using a multivariable Cox proportional hazards (CPH) model, only the nutritional risk 
index score remained associated with increased in-hospital mortality (moderate risk adjusted 
HR 3.99, 95% CI 0.92 to 17.29, p = 0.064; high risk adjusted HR 6.47, 1.44 to 29.09, p = 
0.015). In patients who were being actively managed (167/205), increasing age (adjusted HR 
per year increase 1.07, 95% CI 1.02 to 1.12, p = 0.007) and severe risk of malnutrition 
(adjusted HR 16.18, 95% CI 1.86 to 140.84, p = 0.012) were both independent predictors of 
shortened survival (table 4). In the actively managed cancer population, critical care use was 
not associated with a significant increase or decrease in survival (adjusted HR 1.34, 95% CI 
0.17 to 10.61, p = 0.782, table 3S). 
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Discussion 
NASBO has provided a national level snapshot of current management of patients presenting 
to emergency surgical services with malignant small bowel obstruction. Small bowel 
obstruction due to malignancy is the third most common cause of small bowel obstruction after 
adhesive bowel obstruction and abdominal wall hernia. Outcomes are generally poor, with an 
overall 30-day in-hospital mortality rate of 17.1%, three times that of patients with adhesive 
bowel obstruction[14]. A high number of patients with small bowel obstruction and cancer were 
malnourished, which was independently associated with poorer outcomes and shorter 
survival. Rate of nutritional intervention was relatively low despite the high rates of malnutrition 
seen in this patient group. 
  
In this study, patients with cancer had a high incidence of poor nutritional state, which may 
have been further compounded by obstruction of the gastrointestinal tract impairing absorption 
in patients who also develop small bowel obstruction[15]. Nutritional interventions in this 
patient group are potentially ethically challenging depending on patient, clinician and society 
views on whether nutrition is supportive or therapeutic care. Parenteral nutrition is not 
recommended by some learned societies[16] while other researchers promote benefits of 
goal-directed parenteral nutrition in end of life care[17]  . 
  
In NASBO, we found patients with a primary tumour had a lower mortality rate than those with 
disseminated malignancy (11.3% versus 19.6%); however, patients with primary tumours 
were significantly more likely to suffer complications and require critical care. This observation 
is likely to reflect clinical opinion in favour of surgical resection at first emergency presentation 
with an obstructing primary cancer, with a view to longer-term survival, despite acknowledged 
high short-term morbidity and delay of ileostomy closure[18]. The National Emergency 
Laparotomy Audit has highlighted that surgeon subspecialty is associated with outcomes in 
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emergency laparotomy, particularly with emergency cancer resections[19]. Data on 
subspecialty of operating surgeon was not collected in NASBO, but may be of relevance in 
future studies. 
  
The prevalence of cancer within the emergency surgical population is unsurprising, and in 
keeping with the literature[20]. Small bowel obstruction due to malignancy describes a 
heterogenous range of conditions, including those arising from primary right-sided colonic 
tumours, rare small bowel tumours and disseminated intra-abdominal malignancy[21, 22]. In 
this study, we divided patients by pathology into clear groups to maintain these distinctions. 
Presentation with obstruction may be an indication of advanced disease or slow deterioration 
in enteral intake due to incipient obstruction, which may be reflected in the high mortality rates 
observed. This patient group undoubtedly presents challenges both from an emergency 
surgery and oncological management point-of-view. The high risk of malnutrition found in both 
groups with cancer, in addition to the strong associations of malnutrition risk with poorer 
survival also suggests that our study population are likely presenting with advanced disease 
where late cancer effects such as cachexia and sarcopenia are more common. We found that 
current UK clinical practice favours non-operative management in patients with advanced 
malignancy group. Where surgery is offered in advanced malignancy, diversion with stoma 
formation was more commonly performed than resectional surgery with curative intent. 
  
To this point, the majority of literature describing treatment and outcomes in this high-risk and 
complex group of patients has been limited to single-centre case-series[23], to studies 
focussing on the operative management only[22], or to retrospective coding studies which lack 
prospective near patient data collection[21, 24]. Our study addressed this by undertaking a 
high-quality, prospective, multicentre study to assess current UK surgical practice. 
Furthermore, we collected detailed protocol-driven data, with standardised definitions to 
ensure outcomes were defined in the same way across all centres. Data accuracy was 
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assured through random sampling of 25% of all records in blinded manner, where the local 
data validator did not have access to the initial data entered and was independent from the 
inputting team. This found the overall NASBO dataset to be highly accurate at 92.4%, giving 
high confidence in our findings. Furthermore, NASBO data were concordant with the findings 
of the National Emergency Laparotomy Audit (NELA) in patients with small bowel 
obstruction[25], demonstrating the robust nature of our data and findings. 
  
There are several key limitations which should be considered when interpreting the results of 
our study. Firstly, this study captured patients who presented or were referred to the 
emergency surgery team. Patients may not have been identified if not referred, or if primary 
management of small bowel obstruction was undertaken by another specialty such as 
oncology or the department of medicine for the elderly. Therefore, this study may present a 
conservative estimate of the burden of SBO due to malignancy in the UK. Secondly, although 
this important subgroup was a pre-planned analysis of the larger NASBO study, it was not 
feasible to collect cancer-specific variables such as staging, adjuvant and neoadjuvant 
therapies received. This was due to several factors including the burden that this additional 
detail would place on collaborators who were placed at participating sites for often short 
periods of time, whereas the patient pathway for cancer patients typically spans several 
months. Despite this, the emergency management of advanced cancer patients is poorly 
studied, and we believe our study highlights marked variations in practice, including use of 
imaging, surgery and nutrition. Practices such as therapeutic water-soluble contrast are 
evidence-based in adhesive small bowel obstruction [26], but may be harmful in the context 
when extrapolated to management of complete malignant mechanical small bowel 
obstruction. In future studies, detailed staging and pathology information would be particularly 
useful in patients who presented with a primary neoplasm as a cause for obstruction to 
elucidate how this impacted on management decisions. Nonetheless, this study provides 
robust real-world data demonstrating the breadth of current practice in the UK. 
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There is little randomised evidence studying interventions for patients with malignant small 
bowel obstruction, making clinical decisions challenging[27, 28]. A large prospective study of 
this patient group is required, using an appropriate quality of life measure as the primary 
outcome measure. This could identify treatments associated with improved quality of survival, 
and may better balance upfront short-term risks (likely high) with longer-term quality of survival 
that may be more driven by predictive prognostic variables. Additional clinical questions that 
require answers in this patient group include identifying which patients may benefit from stoma 
diversion, conservative management, and neoadjuvant or palliative chemotherapy, while also 
focussing on role of early enteral or parenteral nutrition. Factors affecting the decision to 
balance the risks when making the clinical decision of primary anastomosis or stoma formation 
should also be explored, as this may significantly impact subsequent morbidity. 
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Figure 1: Patient flow (STROBE) chart showing reasons for exclusion from the main 
dataset 
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Figure 2: Histogram displaying ages of patients who had cancer in NASBO cohort, by 
treatment intent and aetiology 
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Figure 3: Histogram displaying time to surgery for who had cancer in NASBO cohort, 
by treatment intent and aetiology 
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Figure 4: Kaplan-Meier curve demonstrating in hospital survival in those treated 
actively and those undergoing palliation. 
 
 
 
 
 
 
 
  
24 
 
Table 1 – Baseline characteristics of patients included in study 
  
  
Primary 
neoplasm 
(n = 62) 
Disseminated 
malignancy (n 
= 143) 
Post-
operative 
Adhesions 
(n = 1,162) 
p-
value 
Age at admission 
to study (years) 
Mean (SD) 71 (14.4) 67.8 (12.1) 66.7 (17.1) 0.147* 
Sex Male 32 (51.6) 59 (41.3) 496 (42.7) 0.626 
 Female 30 (48.4) 84 (58.7) 663 (57.1)  
 Missing 0 (0.0) 0 (0.0) 3 (0.3)  
Charlson 
Comorbidity 
Index (CCI) 
Mean (SD) 3.6 (6.4) 2.1 (5.1) 3.3 (6) 0.002 
Admission 
Albumin level 
(g/dL) 
Mean (SD) 96.5 
(10.7) 
94.7 (11) 103.3 (10.5) <0.001 
Nutritional Risk 
Index (NRI) 
Low risk 21 (33.9) 43 (30.1) 677 (58.3) <0.001 
 Moderate 
risk 
32 (51.6) 72 (50.3) 304 (26.2)  
 Severe risk 6 (9.7) 20 (14.0) 43 (3.7)  
 Missing 3 (4.8) 8 (5.6) 138 (11.9)  
Accommodation 
prior to 
admission 
Own Home 61 (98.4) 140 (97.9) 1137 (97.8) 0.716 
 Residential 
Home 
1 (1.6) 1 (0.7) 4 (0.3)  
 Nursing 
Home 
0 (0.0) 2 (1.4) 20 (1.7)  
 Missing 0 (0.0) 0 (0.0) 1 (0.1)  
Source of 
referral 
Emergency 
Department 
37 (59.7) 87 (60.8) 825 (71.0) <0.001 
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 General 
Practice 
14 (22.6) 20 (14.0) 223 (19.2)  
 Clinic 
Admission 
3 (4.8) 8 (5.6) 11 (0.9)  
 Referral 
from 
inpatient 
team 
8 (12.9) 28 (19.6) 103 (8.9)  
AKI on 
admission 
No 50 (80.6) 107 (74.8) 918 (79.0) 0.792 
 Yes 12 (19.4) 36 (25.2) 243 (20.9)  
 Missing 0 (0.0) 0 (0.0) 1 (0.1)  
Admission white 
cell count 
(x10^9/L) 
Mean (SD) 11.1 (4.7) 11 (5.6) 11.8 (5) 0.019 
Admission white 
cell count 
< 11.9 x 
10^9 
38 (61.3) 98 (68.5) 668 (57.5) 0.038 
 12.0 to 15.9 
x 10^9 
14 (22.6) 20 (14.0) 300 (25.8)  
 >16.0 x 
10^9 
10 (16.1) 25 (17.5) 194 (16.7)  
 
Values are n (%) unless otherwise specified. AKI – Acute Kidney Injury, SD – Standard 
Deviation. All tests are chi-squared unless otherwise specified by * which denotes Kruskall-
Wallis.  
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Table 2- Management 
 
  
Primary 
neoplasm 
(n = 62) 
Disseminated 
malignancy (n 
= 143) 
Post-
operative 
Adhesions 
(n = 1,162) 
p-
value 
Radiology 
performed 
No 
imaging 
0 (0.0) 1 (0.7) 10 (0.9) 0.004 
 AXR only 4 (6.5) 27 (18.9) 263 (22.6)  
 CT only 12 (19.4) 29 (20.3) 136 (11.7)  
 CT and 
AXR 
46 (74.2) 86 (60.1) 753 (64.8)  
Did the patient 
receive oral or 
rectal water-
soluble contrast 
agent (e.g. 
gastrografin) apart 
from when 
undergoing a CT 
scan? 
No 60 (96.8) 123 (86.0) 805 (69.3) <0.001 
 Yes 2 (3.2) 19 (13.3) 357 (30.7)  
 Missing 0 (0.0) 1 (0.7) 0 (0.0)  
Final treatment 
group 
Non-
operative 
4 (6.5) 66 (46.2) 758 (65.2) <0.001 
 Immediate 
operation 
34 (54.8) 20 (14.0) 136 (11.7)  
 Delayed 
operation 
18 (29.0) 25 (17.5) 256 (22.0)  
 Palliative 6 (9.7) 32 (22.4) 12 (1.0)  
Average time to 
procedure 
Mean (SD) 2.4 (2.8) 5.2 (4.9) 4.5 (8.4) 0.001* 
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Values are n (%) unless otherwise specified. CT – Computed Tomography, AXR – 
Abdominal plain film radiograph, SD – Standard Deviation. All tests are chi-squared unless 
otherwise specified by * which denotes Kruskall-Wallis. 
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Table 3 - Outcomes according to aetiology of bowel obstruction 
  
Primary 
neoplasm 
(n = 62) 
Disseminated 
malignancy (n 
= 143) 
Post-
operative 
Adhesions 
(n = 1,162) p-value 
In hospital 
mortality 
Alive 55 (88.7) 115 (80.4) 1092 
(94.0) 
<0.001 
 Died 7 (11.3) 28 (19.6) 66 (5.7)  
 Missing 0 (0.0) 0 (0.0) 4 (0.3)  
Urinary tract 
infection 
No 55 (88.7) 133 (93.0) 1100 
(94.7) 
0.370 
 Yes- not 
urinary 
catheter 
associated 
4 (6.5) 7 (4.9) 32 (2.8)  
 Yes- urinary 
catheter 
associated 
3 (4.8) 3 (2.1) 27 (2.3)  
 Missing 0 (0.0) 0 (0.0) 3 (0.3)  
Lower respiratory 
tract infection 
No 51 (82.3) 127 (88.8) 1030 
(88.6) 
0.585 
 Yes 11 (17.7) 16 (11.2) 130 (11.2)  
 Missing 0 (0.0) 0 (0.0) 2 (0.2)  
Deep surgical site 
infection 
No 56 (90.3) 141 (98.6) 1131 
(97.3) 
0.012 
 Yes 6 (9.7) 2 (1.4) 29 (2.5)  
 Missing 0 (0.0) 0 (0.0) 2 (0.2)  
Superficial 
surgical site 
infection 
No 54 (87.1) 136 (95.1) 1105 
(95.1) 
0.077 
 Yes 8 (12.9) 7 (4.9) 55 (4.7)  
 Missing 0 (0.0) 0 (0.0) 2 (0.2)  
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Abdominal wall 
dehiscence 
No 59 (95.2) 141 (98.6) 1141 
(98.2) 
0.235 
 Yes 3 (4.8) 2 (1.4) 16 (1.4)  
 Missing 0 (0.0) 0 (0.0) 5 (0.4)  
Anastomotic leak No 62 
(100.0) 
143 (100.0) 1154 
(99.3) 
0.841 
 Yes 0 (0.0) 0 (0.0) 6 (0.5)  
 Missing 0 (0.0) 0 (0.0) 2 (0.2)  
Radiologically 
guided drainage 
No 57 (91.9) 139 (97.2) 1145 
(98.5) 
0.001 
 Yes 5 (8.1) 4 (2.8) 14 (1.2)  
 Missing 0 (0.0) 0 (0.0) 3 (0.3)  
Venous 
thromboembolism 
(PE or DVT) 
No 60 (96.8) 136 (95.1) 1152 
(99.1) 
<0.001 
 Yes 2 (3.2) 7 (4.9) 6 (0.5)  
 Missing 0 (0.0) 0 (0.0) 4 (0.3)  
Delirium No 60 (96.8) 137 (95.8) 1111 
(95.6) 
0.956 
 Yes 2 (3.2) 6 (4.2) 48 (4.1)  
 Missing 0 (0.0) 0 (0.0) 3 (0.3)  
Cardiovascular 
event (MI, new 
heart block, 
Stroke, TIA) 
No 56 (90.3) 140 (97.9) 1101 
(94.8) 
0.168 
 Yes 6 (9.7) 3 (2.1) 56 (4.8)  
 Missing 0 (0.0) 0 (0.0) 5 (0.4)  
Reoperation No 55 (88.7) 75 (52.4) 379 (32.6) <0.001 
 Yes 3 (4.8) 2 (1.4) 22 (1.9)  
 Missing 4 (6.5) 66 (46.2) 761 (65.5)  
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Unplanned 
HDU/ITU 
admission 
No 55 (88.7) 134 (93.7) 1064 
(91.6) 
0.843 
 Yes- 
Intensive 
Care Unit 
4 (6.5) 6 (4.2) 55 (4.7)  
 Yes- High 
Dependency 
Care 
3 (4.8) 3 (2.1) 37 (3.2)  
 Missing 0 (0.0) 0 (0.0) 6 (0.5)  
Readmission 
within 30-days 
No 54 (87.1) 116 (81.1) 991 (85.3) 0.361 
 Yes 6 (9.7) 25 (17.5) 142 (12.2)  
 Missing 2 (3.2) 2 (1.4) 29 (2.5)  
Length of stay 
(days) 
Mean (SD) 13.6 (8.2) 14.8 (14.6) 9.8 (12.4) <0.001* 
Values are n (%) unless otherwise specified. SD – Standard Deviation. All tests are chi-
squared unless otherwise specified by * which denotes Kruskall-Wallis. 
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Table 4 - Determinants of survival 
  HR (univariable) HR (multivariable) 
Initial management 
strategy 
Non-
operative 
- - 
 Operative 0.61 (0.24-1.52, 
p=0.289) 
0.41 (0.13-1.25, 
p=0.118) 
 Palliative 1.43 (0.56-3.65, 
p=0.450) 
0.88 (0.33-2.35, 
p=0.802) 
Age at admission to study 
(years) 
Mean (SD) 1.03 (1.00-1.06, 
p=0.081) 
1.02 (0.98-1.06, 
p=0.286) 
Sex Male - - 
 Female 0.73 (0.36-1.47, 
p=0.375) 
1.24 (0.52-2.99, 
p=0.631) 
Charlson Comorbidity 
Index (CCI) 
Mean (SD) 1.05 (1.00-1.10, 
p=0.047) 
1.04 (0.99-1.09, 
p=0.119) 
Nutritional Risk Index 
(NRI) 
Low risk - - 
 Moderate 
risk 
5.17 (1.20-22.22, 
p=0.027) 
3.99 (0.92-17.29, 
p=0.064) 
 Severe risk 9.25 (1.98-43.15, 
p=0.005) 
6.47 (1.44-29.09, 
p=0.015) 
Admission white cell 
count (x10^9/L) 
Mean (SD) 1.03 (0.97-1.09, 
p=0.313) 
- 
Effect estimates are presented as hazard ratios (HR) alongside the corresponding 95% 
confidence interval. SD – Standard Deviation. 
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Supplement 
Table 1S - Aetiologies 
 
 
Non-
operative (n 
= 70) 
Immediate 
operation (n = 
54) 
Delayed 
operation (n = 
43) 
Palliative 
(n = 38) 
Right sided colonic 
cancer 
3 (4.3) 27 (50.0) 15 (34.9) 5 (13.2) 
Disseminated intra-
abdominal malignancy 
66 (94.3) 20 (37.0) 25 (58.1) 32 (84.2) 
Small Bowel 
Malignancy 
1 (1.4) 5 (9.3) 3 (7.0) 1 (2.6) 
Gastrointestinal 
Stromal Tumour 
0 (0.0) 2 (3.7) 0 (0.0) 0 (0.0) 
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Table 2S – Nutritional characteristics and interventions of included patients 
  
Low 
risk (n 
= 64) 
Moderate 
risk (n = 
104) 
Severe 
risk (n = 
26) 
p-
value 
Malnourished No 30 
(46.9) 
60 (57.7) 12 (46.2) 0.549 
 Yes 33 
(51.6) 
41 (39.4) 13 (50.0)  
 Missing 1 (1.6) 3 (2.9) 1 (3.8)  
Malnutrition risk 
assessment 
Assessed 53 
(82.8) 
78 (75.0) 23 (88.5) 0.224 
 Not 
Assessed 
11 
(17.2) 
26 (25.0) 3 (11.5)  
Was the patient assessed 
for malnutrition using 
Clinical Judgement? 
No 11 
(17.2) 
23 (22.1) 7 (26.9) 0.493 
 Yes 42 
(65.6) 
57 (54.8) 12 (46.2)  
 Not 
Assessed 
11 
(17.2) 
24 (23.1) 7 (26.9)  
Was the patient assessed 
for malnutrition using a 
Nutritional Assessment 
Tool? 
No 16 
(25.0) 
30 (28.8) 4 (15.4) 0.487 
 Yes 39 
(60.9) 
56 (53.8) 19 (73.1)  
 Not 
Assessed 
9 (14.1) 18 (17.3) 3 (11.5)  
Was the patient reviewed 
by a dietitian or nutrition 
team at any point during 
admission 
No 36 
(56.2) 
68 (65.4) 15 (57.7) 0.615 
 Yes 28 
(43.8) 
35 (33.7) 11 (42.3)  
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 Missing 0 (0.0) 1 (1.0) 0 (0.0)  
Time to review by dietician 
(days) 
Mean 
(SD) 
6.4 
(6.4) 
8.2 (8.7) 3.6 (2.8) 0.209* 
Nutritional Intervention No 29 
(45.3) 
63 (60.6) 15 (57.7) 0.292 
 Yes 35 
(54.7) 
40 (38.5) 11 (42.3)  
 Missing 0 (0.0) 1 (1.0) 0 (0.0)  
Were oral supplements 
(e.g. fortisips) started at 
any point during admission 
No 33 
(51.6) 
73 (70.2) 21 (80.8) 0.034 
 Yes 31 
(48.4) 
30 (28.8) 5 (19.2)  
 Missing 0 (0.0) 1 (1.0) 0 (0.0)  
Was NG or NJ feed started 
at any point during 
admission 
No 62 
(96.9) 
97 (93.3) 23 (88.5) 0.505 
 Yes 2 (3.1) 6 (5.8) 3 (11.5)  
 Missing 0 (0.0) 1 (1.0) 0 (0.0)  
Was TPN started at any 
point during the admission 
No 55 
(85.9) 
92 (88.5) 22 (84.6) 0.822 
 Yes 9 (14.1) 12 (11.5) 4 (15.4)  
 
Values are n (%) unless otherwise specified. TPN – Total Parenteral Nutrition, NG – 
Nasogastric, NJ- Nasojejunal, SD – Standard Deviation. All tests are chi-squared unless 
otherwise specified by * which denotes Kruskall-Wallis.  
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Table 3S – Determinants of survival after Critical Care in non-palliative patients 
  HR (univariable) HR (multivariable) 
Unplanned critical care No - - 
 Yes 0.89 (0.12-6.64, 
p=0.909) 
1.34 (0.17-10.61, 
p=0.782) 
Age at admission to 
study (years) 
Mean (SD) 1.07 (1.03-1.12, 
p=0.001) 
1.07 (1.02-1.12, 
p=0.007) 
Sex Male - - 
 Female 0.70 (0.29-1.67, 
p=0.418) 
0.82 (0.33-2.02, 
p=0.660) 
Charlson Comorbidity 
Index (CCI) 
Mean (SD) 1.02 (0.95-1.09, 
p=0.547) 
1.03 (0.95-1.11, 
p=0.510) 
Nutritional Risk Index 
(NRI) 
Low risk - - 
 Moderate 
risk 
7.95 (1.22-51.66, 
p=0.030) 
4.36 (0.63-30.35, 
p=0.137) 
 Severe risk 14.28 (1.87-108.83, 
p=0.010) 
16.18 (1.86-140.84, 
p=0.012) 
Effect estimates are presented as hazard ratios (HR) alongside the corresponding 95% 
confidence interval. 
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